Price
$322.10+14.28%Social Signal Score
Analyst Ratings
28 analystsRevenue
$752.75M+1296.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven Leonard Chapman
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 6,138
- Beta
- 1.53
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 41.85
Financials
Revenue
$752.75M+1296.9%Net Income
$-66.97MEBITDA
$-45.15MFree Cash Flow
$-8.64MEPS (diluted)
$-0.47Shares Outstanding (diluted)
143.28M+175.5%Operating Expenses
$555.27MCash & Debt
$1.09BRevenue by Segment (annual)
$2.31BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.31B | $-208.16M | $-1.52 |
| 2024 | $1.70B | $-190.43M | $-1.53 |
| 2023 | $1.08B | $-434.80M | $-3.78 |
| 2022 | $820.22M | $-547.80M | $-5.57 |
| 2021 | $625.49M | $-471.72M | $-5.21 |
| 2020 | $391.00M | $-229.74M | $-2.84 |
| 2019 | $302.33M | $-124.83M | $-1.79 |
| 2018 | $257.65M | $-128.15M | $-2.22 |
| 2017 | $210.94M | $-136.31M | $-2.56 |
| 2016 | $217.07M | $-95.77M | $-1.86 |
| 2015 | $190.35M | $-70.28M | $-1.47 |
| 2014 | $159.29M | $-5.15M | $-0.14 |
| 2013 | $55.17M | $-37.11M | $-1.01 |
| 2012 | $14.25M | $-76.17M | $-24.37 |
Valuation
NTRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
73+143.34%Social Signal Score
Mentions (24)
- News (Marketaux)gurufocus.com·11h ago·Positive
Natera Inc (NTRA) Shares Surge 3.7% -- What GF Score of 71 Tells Investors On October 05, 2026, Natera <em[+228 characters]
View source ↗ - Newsbenzinga.com·8d ago·Neutral
Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE:HPE).
View source ↗ - Newszacks.com·12d ago·Neutral
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
View source ↗ - News (Marketaux)gurufocus.com·13d ago·Positive
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 On September 22, 2026, Natera <[+249 characters]
View source ↗ - News (RSS)investing·13d ago·Neutral
Natera Inc stock reaches all-time high at 373.58 USD
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·15d ago·Positive
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)rttnews.com·18d ago·Positive
Show Me The Money: Natera Delivers Over 120% Gain In Just About A Year For Natera Inc. (NTRA)[+266 characters]
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MR…
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymp…
View source ↗ - News (RSS)yahoo·38d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
View source ↗ - News (RSS)fool·38d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? The billionaire has good reasons to like this genetic testing leader.
View source ↗ - Newsfool.com·38d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? The billionaire has good reasons to like this genetic testing leader.
View source ↗ - Newsbusinesswire.com·38d ago·Positive
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD t…
View source ↗ - News (Marketaux)finance.yahoo.com·42d ago·Positive
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either. It was a genetic testing company called [+275 characters]
View source ↗ - News (Marketaux)seekingalpha.com·47d ago·Positive
Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share (NASDAQ:NTRA) Natera ( NTRA ) had a fantastic[+263 characters]
View source ↗ - Newszacks.com·49d ago·Neutral
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
View source ↗ - Newsmarketbeat.com·51d ago·Negative
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - News (RSS)investing·55d ago·Neutral
Natera partners with Kupando for phase 1 cancer trial in Germany
View source ↗ - Newsbusinesswire.com·55d ago·Negative
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy ca
View source ↗ - Newsfool.com·58d ago·Positive
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead. Druckenmiller only owns one "Magnificent Seven" stock.
View source ↗ - Newsforbes.com·59d ago·Negative
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status 40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shares fell to $182.65.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.24 per share
Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.47 vs $-0.49beat
- Thu, May 7$-0.56 vs $-0.54miss
- Thu, Feb 26$0.35 vs $-0.51beat
- Thu, Nov 6$-0.64 vs $-0.39miss
- Thu, Aug 7$-0.74 vs $-0.62miss
- Thu, May 8$-0.50 vs $-0.64beat
Estimates and results for NTRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NTRA officers and directors.
- Bought
- —
- Sold
- $79.7m
0 trades
98 trades
- Chapman Steven Leonardsold
- Moshkevich Solomonsold
- Moshkevich Solomonsold
- Moshkevich Solomonsold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
2 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 16, 2025 (24d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Sep 8, 2025 (17d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 12, 2025 (21d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 6, 2024 (16d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$1,001 - $15,000
- William Francis Hagertysenate · TN · disclosed May 4, 2021 (14d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.